Monash agreement with Immuron on SARS-CoV-2 research creates a buzz
Business publications eagerly reported the news that Australian bio pharmaceutical company Immuron (IMC) had entered a research agreement with Monash University to analyse the IMM-124E drug and its relevance to SARS-CoV-2. IMM-124E is the active pharmaceutical ingredient used to make Immuron's over-the-counter gastrointestinal and digestive health products, Travelan and Protectyn, The Market Herald reported.
The research team will be led by Monash BDI's Dr Melanie Hutton and Professor Dena Lyras.
Professor Lyras will obtain a SARS-CoV-2 Spike protein and an antibody-positive human serum to research the inhibitory efficacy of Immuron's drug.
Travelan and Protectyn work by relieving traveller's diarrhoea and supporting digestive health, however, the IMM-124E drug has shown antiviral activity against SARS-CoV-2, the virus that causes COVID-19, the publication wrote. While COVID-19 patients are known to have respiratory problems, symptoms like diarrhoea, vomiting and cramping have also been observed. The news was also reported by FirstWord Pharma, MENAFN and Kalkin Media.